Intravenous Segment to Dominate South and Central America Generic Injectables Market during 2019–2028

According to a new market research study on “South and Central America Generic Injectables Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product Type, Container Type, Application, and Route of Administration,” is expected to reach US$ 8,567.51 million by 2028 from US$ 4,513.94 million in 2021. The market is estimated to grow at a CAGR of 9.6% from 2021 to 2028. Government support for generic injectables production and healthcare cost reduction is the major factor driving the growth of the South and Central America generic injectables market. However, critical inspection system for prefilled injection may hinder the growth of South and Central America generic injectables market. The report provides trends prevailing in the South and Central America generic injectables market along with the drivers and restraints pertaining to the market growth.

The South and Central America generic injectables market is segmented into product type, container type, application, route of administration, and country. The South and Central America generic injectables market, based on product type, has been segmented into large molecule injectable and small molecule injectable. In 2020, the large molecule injectable segment held the largest share South and Central America generic injectables market. The South and Central America generic injectables market, based on container type, has been categorized into vials, premix, prefilled syringes, ampoules, and others. In 2020, the vials segment held the largest share South and Central America generic injectables market. The South and Central America generic injectables market, based on application, has been categorized into oncology, infectious diseases, cardiology, diabetes, immunology, and others. In 2020, the oncology segment held the largest share South and Central America generic injectables market. The South and Central America generic injectables market, based on route of administration, has been categorized into intravenous, intramuscular, subcutaneous, and others. In 2020, the intravenous segment held the largest share South and Central America generic injectables market. Similarly, based on country, the South and Central America generic injectables market is segmented into the Brazil, Argentina, and the rest of South and Central America. Brazil contributed a substantial share in 2020. 

AstraZeneca; Baxter International Inc.; Biocon; Fresenius SE & Co. KGaA; GlaxoSmithKline plc; Johnson and Johnson Services, Inc.; Lupin; Merck & Co., Inc.; Pfizer Inc.; and Viatris Inc are among the leading companies in the South and Central America generic injectables market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2017, Baxter International Inc. and ScinoPharm Taiwan, Ltd. announced a strategic partnership to develop, manufacture and commercialize 5 injectable drugs used in a variety of cancer treatments, including multiple myeloma, lung cancer, and breast cancer, also in medication to treat vomiting, nausea, and other common side effects of chemotherapy.

South and Central America Generic Injectables Market, By Country, 2020 and 2028 (%)

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com